ImmuLogic Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmuLogic

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Paul Getman who wrote (7)	9/24/1996 5:00:00 PM
From: David Bleich	of 23

Paul: This is great news. My clinical impression is that most patients with significant allergies will happily dose themselves 2-3 times weekly. The allegy season in L.A. has been vicious which highlights the need for better therapies. Every drug company gets out another me-to antihistamine(the most recent is Zyrtec by Pfiszer) which all have idenical pharmacology and really don't work that well. My old tried and true standby is Benedryl which really does have significant sedative side-effects. I think a target price of $18/share is ridiculously conservative. Look at Vertex Pharmaceutical, which has HIV protease inhibitor #6, behind Merck, Glaxo, etc... and an not so great pipeline, trading at $31/share. Then look at Genzyme which started back in 1988-1989 with ceridase (glucocerebrosidase inhibitor used to treat a relatively rare disease called Gaucher's disease). The market cap for ceridase was estimated to be about $15-30 million/year and that took Genzyme from a $7-8/share stock to ~$30/share. Now look what has happened since. I think that IMUL will be good for $25-30 with FDA approval for Allervax and then the new cash flow will let their already robust pipeline gush. Am I too optimistic or on the mark?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next